CoChat
Sign Up
Cited by 97Cancer Cells and MetastasisDevelopmental Biology and Gene RegulationPluripotent Stem Cells Research

SOX9 stem-cell factor: clinical and functional relevance in cancer

Open access
Aguilar-Medina, Maribel, Avendaño-Félix, Mariana, Lizárraga-Verdugo, Erik, Bermúdez, Mercedes, Romero-Quintana, José Geovanni, Ramos-Payan, Rosalío, Ruíz-García, Erika, López-Camarillo, César·2019·Journal of Oncology
DOI 10.1155/2019/6754040PMC PMC6463569
Open this paper in CoChat — free accountOpen PDF

Abstract

Transcriptional and epigenetic embryonic programs can be reactivated in cancer cells. As result, a specific subset of undifferentiated cells with stem-cells properties emerges and drives tumorigenesis. Recent findings have shown that ectoderm- and endoderm-derived tissues continue expressing stem-cells related transcription factors of the SOX-family of proteins such as SOX2 and SOX9 which have been implicated in the presence of cancer stem-like cells (CSCs) in tumors. Currently, there is enough evidence suggesting an oncogenic role for SOX9 in different types of human cancers. This review provides a summary of the current knowledge about the involvement of SOX9 in development and progression of cancer. Understanding the functional roles of SOX9 and clinical relevance is crucial for developing novel treatments targeting CSCs in cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2019/6754040

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • SOX9 can drive cancer invasion and metastasis in multiple cancers, including prostate, breast, colon, gastric, and lung.

    “SOX9 can drive cancer invasion and metastasis in multiple cancers, including prostate, breast, colon, gastric, and lung (summarized in (13))”

    From SOX9 reprograms endothelial cells by altering the chromatin landscape (2022) · cites this paper as [13]

    The Concluding Remarks (no page supplied) link SOX9 to metastasis in breast, gastric, and colorectal cancer. Section 3.4 describes its promotion of gastric invasion and metastasis, and section 3.6 suggests a role in prostate invasion. The cited paper does not establish the claimed invasion-and-metastasis role in lung cancer, and its prostate discussion does not establish metastasis. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 156

  1. [1]Beck B. Blanpain C. Unravelling cancer stem cell potential Nature Reviews Cancer 2013 13 10 727 738 2-s2.0-84884558125 10.1038/nrc3597 24060864 · DOI
  2. [2]Kuşoğlu A. Biray Avcı Ç. Cancer stem cells: a brief review of the current status Gene 2019 681 80 85 10.1016/j.gene.2018.09.052 30268439 · DOI
  3. [3]Sekido R. Lovell-Badge R. Sex determination and SRY: down to a wink and a nudge? Trends in Genetics 2009 25 1 19 29 2-s2.0-58149333236 10.1016/j.tig.2008.10.008 19027189 · DOI
  4. [4]Wegner M. All purpose sox: the many roles of sox proteins in gene expression The International Journal of Biochemistry & Cell Biology 2010 42 3 381 390 10.1016/j.biocel.2009.07.006 2-s2.0-76549090706 19631281 · DOI
  5. [5]Wang H.-Y. Lian P. Zheng P.-S. SOX9, a potential tumor suppressor in cervical cancer, transactivates p21WAF1/CIP1 and suppresses cervical tumor growth Oncotarget 2015 6 24 20711 20722 2-s2.0-84940213156 26036262 PMC4653037
  6. [6]Prévostel C. Rammah-Bouazza C. Trauchessec H. SOX9 is an atypical intestinal tumor suppressor controlling the oncogenic Wnt/ss-catenin signaling Oncotarget 2016 7 50 82228 82243 10.18632/oncotarget.10573 27429045 PMC5347687 · DOI
  7. [7]Jo A. Denduluri S. Zhang B. The versatile functions of Sox9 in development, stem cells, and human diseases Genes & Diseases 2014 1 2 149 161 25685828 PMC4326072
  8. [8]Luanpitpong S. Li J. Manke A. SLUG is required for SOX9 stabilization and functions to promote cancer stem cells and metastasis in human lung carcinoma Oncogene 2016 35 22 2824 2833 2-s2.0-84973326459 10.1038/onc.2015.351 26387547 PMC4801727 · DOI
  9. [9]Guo W. Keckesova Z. Donaher J. L. Slug and Sox9 cooperatively determine the mammary stem cell state Cell 2012 148 5 1015 1028 10.1016/j.cell.2012.02.008 2-s2.0-84857817163 22385965 PMC3305806 · DOI
  10. [10]Voronkova M. A. Luanpitpong S. Rojanasakul L. W. SOX9 regulates cancer stem-like properties and metastatic potential of single-walled carbon nanotube-exposed cells Scientific Reports 2017 7 1 p. 11653 10.1038/s41598-017-12037-8 PMC5599589 28912540 · DOI
  11. [11]Sinclair A. H. Berta P. Palmer M. S. A gene from the human sex-determining region encodes a protein with homology to a conserved DNA-binding motif Nature 1990 346 6281 240 244 2-s2.0-0025364886 10.1038/346240a0 1695712 · DOI
  12. [12]Symon A. Harley V. SOX9: A genomic view of tissue specific expression and action The International Journal of Biochemistry & Cell Biology 2017 87 18 22 28323209
  13. [13]Badis G. Berger M. F. Philippakis A. A. Diversity and complexity in DNA recognition by transcription factors Science 2009 324 5935 1720 1723 10.1126/science.1162327 19443739 PMC2905877 · DOI
  14. [14]Wegner M. From head to toes: the multiple facets of Sox proteins Nucleic Acids Research 1999 27 6 1409 1420 10.1093/nar/27.6.1409 2-s2.0-0033559518 10037800 PMC148332 · DOI
  15. [16]Sim H. Argentaro A. Harley V. R. Boys, girls and shuttling of SRY and SOX9 Trends in Endocrinology & Metabolism 2008 19 6 213 222 2-s2.0-47249149614 10.1016/j.tem.2008.04.002 18585925 · DOI
  16. [17]Peng C. Li N. Ng Y.-K. A unilateral negative feedback loop between miR-200 microRNAs and Sox2/E2F3 controls neural progenitor cell-cycle exit and differentiation The Journal of Neuroscience 2012 32 38 13292 13308 10.1523/jneurosci.2124-12.2012 2-s2.0-84866414208 22993445 PMC3752087 · DOI
  17. [18]Oosterveen T. Kurdija S. Alekseenko Z. Mechanistic differences in the transcriptional interpretation of local and long-range shh morphogen signaling Developmental Cell 2012 23 5 1006 1019 10.1016/j.devcel.2012.09.015 2-s2.0-84869032400 23153497 · DOI
  18. [19]Bernard P. Harley V. R. Acquisition of SOX transcription factor specificity through protein-protein interaction, modulation of Wnt signalling and post-translational modification The International Journal of Biochemistry & Cell Biology 2010 42 3 400 410 2-s2.0-76749130545 10.1016/j.biocel.2009.10.017 19854293 · DOI
  19. [20]Sarkar A. Hochedlinger K. The SOX family of transcription factors: versatile regulators of stem and progenitor cell fate Cell Stem Cell 2013 12 1 15 30 10.1016/j.stem.2012.12.007 2-s2.0-84872046078 23290134 PMC3608206 · DOI
  20. [21]Scott C. E. Wynn S. L. Sesay A. SOX9 induces and maintains neural stem cells Nature Neuroscience 2010 13 10 1181 1189 10.1038/nn.2646 20871603 · DOI
  21. [22]Guo X. Xiong L. Sun T. Expression features of SOX9 associate with tumor progression and poor prognosis of hepatocellular carcinoma Diagnostic Pathology 2012 7 1, article 44 10.1186/1746-1596-7-44 2-s2.0-84865124257 PMC3464896 22515642 · DOI
  22. [23]Richtig G. Aigelsreiter A. Schwarzenbacher D. SOX9 is a proliferation and stem cell factor in hepatocellular carcinoma and possess widespread prognostic significance in different cancer types PLoS ONE 2017 12 11 p. e0187814 10.1371/journal.pone.0187814 29121666 PMC5679634 · DOI
  23. [24]Chakravarty G. Rider B. Mondal D. Cytoplasmic compartmentalization of SOX9 abrogates the growth arrest response of breast cancer cells that can be rescued by Trichostatin A treatment Cancer Biology & Therapy 2011 11 1 71 83 2-s2.0-78751475720 10.4161/cbt.11.1.13952 21084857 · DOI
  24. [25]Wan Y.-P. Xi M. He H.-C. Expression and clinical significance of SOX9 in renal cell carcinoma, bladder cancer and penile cancer Oncology Research and Treatment 2017 40 1-2 15 20 10.1159/000455145 2-s2.0-85010918108 28118628 · DOI
  25. [26]Santos J. C. Carrasco-Garcia E. Garcia-Puga M. SOX9 elevation acts with canonical WNT signaling to drive gastric cancer progression Cancer Research 2016 76 22 6735 6746 2-s2.0-84995470001 10.1158/0008-5472.CAN-16-1120 27569216 · DOI
  26. [27]Song W. Kwon G. Y. Kim J. H. Immunohistochemical staining of ERG and SOX9 as potential biomarkers of docetaxel response in patients with metastatic castration-resistant prostate cancer Oncotarget 2016 7 50 83735 83743 2-s2.0-85004019898 27863438 PMC5347800
  27. [28]Burdelski C. Bujupi E. Tsourlakis M. C. Loss of SOX9 expression is associated with PSA recurrence in ERG-positive and pten deleted prostate cancers PLoS ONE 2015 10 6 e0128525 10.1371/journal.pone.0128525 PMC4452277 26030748 · DOI
  28. [29]Raspaglio G. Petrillo M. Martinelli E. Sox9 and Hif-2α regulate TUBB3 gene expression and affect ovarian cancer aggressiveness Gene 2014 542 2 173 181 10.1016/j.gene.2014.03.037 24661907 · DOI
  29. [30]Miura K. Kimura K. Amano R. Analysis of the origin of anaplastic pancreatic cancer and the mechanism of its dedifferentiation Journal of Hepato-Biliary-Pancreatic Sciences 2017 24 3 176 184 2-s2.0-85013455427 10.1002/jhbp.429 28064441 · DOI
  30. [31]Lü B. Fang Y. Xu J. Analysis of SOX9 expression in colorectal cancer American Journal of Clinical Pathology 2008 130 6 897 904 2-s2.0-58049208376 10.1309/AJCPW1W8GJBQGCNI 19019766 · DOI
  31. [32]Marcker Espersen M. L. Linnemann D. Christensen I. J. Alamili M. Troelsen J. T. Høgdall E. SOX9 expression predicts relapse of stage II colon cancer patients Human Pathology 2016 52 38 46 2-s2.0-84961821468 10.1016/j.humpath.2015.12.026 26980019 · DOI
  32. [33]Xicola R. M. Manojlovic Z. Augustus G. J. Lack of APC somatic mutation is associated with early-onset colorectal cancer in African Americans Carcinogenesis 2018 39 11 1331 1341 10.1093/carcin/bgy122 30239619 PMC6292413 · DOI
  33. [34]Prévot P.-P. Simion A. Grimont A. Role of the ductal transcription factors HNF6 and Sox9 in pancreatic acinar-to-ductal metaplasia Gut 2012 61 12 1723 1732 2-s2.0-84868698484 10.1136/gutjnl-2011-300266 22271799 PMC3898034 · DOI
  34. [35]Hessmann E. Zhang J.-S. Chen N.-M. NFATc4 Regulates Sox9 gene expression in acinar cell plasticity and pancreatic cancer initiation Stem Cells International 2016 2016 11 5272498 2-s2.0-84949967577 PMC4677249 26697077
  35. [36]Jeannot P. Callot C. Baer R. Loss of p27Kip1 promotes metaplasia in the pancreas via the regulation of Sox9 expression Oncotarget 2015 6 34 35880 35892 2-s2.0-84946893384 26416424 PMC4742148
  36. [37]Kopp J. L. von Figura G. Mayes E. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma Cancer Cell 2012 22 6 737 750 10.1016/j.ccr.2012.10.025 2-s2.0-84870803922 23201164 PMC3568632 · DOI · Paper page
  37. [38]Xia S. Feng Z. Qi X. Clinical implication of Sox9 and activated Akt expression in pancreatic ductal adenocarcinoma Medical Oncology 2015 32 1 p. 358 10.1007/s12032-014-0358-0 25428381 · DOI
  38. [39]Huang L. Holtzinger A. Jagan I. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids Nature Medicine 2015 21 11 p. 1364 PMC4753163 26501191
  39. [40]Sun L. Mathews L. A. Cabarcas S. M. Epigenetic regulation of SOX9 by the NF-κB signaling pathway in pancreatic cancer stem cells Stem Cells 2013 31 8 1454 1466 10.1002/stem.1394 2-s2.0-84883410708 23592398 PMC3775871 · DOI
  40. [41]Schultz M. J. Holdbrooks A. T. Chakraborty A. The tumor-associated glycosyltransferase ST6Gal-I regulates stem cell transcription factors and confers a cancer stem cell phenotype Cancer Research 2016 76 13 3978 3988 2-s2.0-84977578357 10.1158/0008-5472.CAN-15-2834 27216178 PMC4930726 · DOI
  41. [42]Higashihara T. Yoshitomi H. Nakata Y. Sex determining region y box 9 induces chemoresistance in pancreatic cancer cells by induction of putative cancer stem cell characteristics and its high expression predicts poor prognosis Pancreas 2017 46 10 1296 1304 10.1097/MPA.0000000000000945 2-s2.0-85032214100 28984791 · DOI
  42. [43]Deng W. Vanderbilt D. B. Lin C. Martin K. H. Brundage K. M. Ruppert J. M. SOX9 inhibits beta-TrCP-mediated protein degradation to promote nuclear GLI1 expression and cancer stem cell properties Journal of Cell Science 2015 128 6 1123 1138 10.1242/jcs.162164 25632159 PMC4359920 · DOI
  43. [44]Kondratyeva L. G. Sveshnikova A. A. Grankina E. V. Downregulation of expression of mater genes SOX9, FOXA2, and GATA4 in pancreatic cancer cells stimulated with TGFβ1 epithelial–mesenchymal transition Doklady Biochemistry and Biophysics 2016 469 1 257 259 10.1134/S1607672916040062 27599506 · DOI
  44. [45]Pinho A. V. Rooman I. Real F. X. p53-dependent regulation of growth, epithelial-mesenchymal transition and stemness in normal pancreatic epithelial cells Cell Cycle 2011 10 8 1312 1321 2-s2.0-79954538151 10.4161/cc.10.8.15363 21490434 · DOI
  45. [46]Camaj P. Jackel C. Krebs S. Hypoxia-independent gene expression mediated by SOX9 promotes aggressive pancreatic tumor biology Molecular Cancer Research 2014 12 3 421 432 2-s2.0-84897041593 10.1158/1541-7786.MCR-13-0351 24302456 · DOI
  46. [47]Meng F. Takaori K. Ito T. Expression of SOX9 in intraductal papillary mucinous neoplasms of the pancreas Pancreas 2014 43 1 7 14 2-s2.0-84891528892 10.1097/MPA.0b013e3182a70b2f 24212241 · DOI
  47. [48]Galmiche L. Sarnacki S. Verkarre V. Transcription factors involved in pancreas development are expressed in paediatric solid pseudopapillary tumours Histopathology 2008 53 3 318 324 2-s2.0-50049106706 10.1111/j.1365-2559.2008.03108.x 18671802 · DOI
  48. [49]Javier B. M. Yaeger R. Wang L. Recurrent, truncating Sox9 mutations are associated with sox9 overexpression, KRAS mutation, and TP53 wild type status in colorectal carcinoma Oncotarget 2016 7 32 50875 50882 2-s2.0-84982311338 27248473 PMC5239443
  49. [50]Al-Kuraya K. S. Editorial: KRAS and TP53 mutations in colorectal carcinoma Saudi Journal of Gastroenterology 2009 15 4 217 219 10.4103/1319-3767.56087 2-s2.0-70349823495 19794264 PMC2981835 · DOI
  50. [51]Abdel-Samad R. Zalzali H. Rammah C. MiniSOX9, a dominant-negative variant in colon cancer cells Oncogene 2011 30 22 2493 2503 2-s2.0-79957903265 10.1038/onc.2010.621 21297661 · DOI
  51. [52]Panza A. Interplay between SOX9, beta-catenin and PPARgamma activation in colorectal cancer Biochimica et Biophysica Acta Aug 2013 1833 8 1853 65 10.1016/j.bbamcr.2013.04.004 23583560 · DOI
  52. [53]Shi Z. Chiang C.-I. Labhart P. Context-specific role of SOX9 in NF-Y mediated gene regulation in colorectal cancer cells Nucleic Acids Research 2015 43 13 6257 6269 2-s2.0-84939612700 10.1093/nar/gkv568 26040697 PMC4513854 · DOI
  53. [54]Qian Y. Xia S. Feng Z. Sox9 mediated transcriptional activation of FOXK2 is critical for colorectal cancer cells proliferation Biochemical and Biophysical Research Communications 2017 483 1 475 481 2-s2.0-85008487954 10.1016/j.bbrc.2016.12.119 28007600 · DOI
  54. [55]Shen Z. Deng H. Fang Y. Identification of the interplay between SOX9 and S100P in the metastasis and invasion of colon carcinoma Oncotarget 2015 6 24 20672 20684 10.18632/oncotarget.3967 26009899 PMC4653034 · DOI
  55. [56]Choi B. Park S. Lee S. Cha Y. N. Surh Y. Hypoxia induces epithelial-mesenchymal transition in colorectal cancer cells through ubiquitin-specific protease 47-mediated stabilization of Snail: A potential role of Sox9 Scientific Reports 2017 7 1 10.1038/s41598-017-15139-5 PMC5698333 29162839 · DOI
  56. [57]Carrasco-Garcia E. Lopez L. Aldaz P. SOX9-regulated cell plasticity in colorectal metastasis is attenuated by rapamycin Scientific Reports 2016 6 1 p. 32350 10.1038/srep32350 PMC5004104 27571710 · DOI
  57. [58]Fazilaty H. Gardaneh M. Akbari P. Zekri A. Behnam B. SLUG and SOX9 cooperatively regulate tumor initiating niche factors in breast cancer Cancer Microenvironment 2016 9 1 71 74 10.1007/s12307-015-0176-8 2-s2.0-84944706948 26412079 PMC4842180 · DOI
  58. [59]Chakravarty G. Moroz K. Makridakis N. M. Prognostic significance of cytoplasmic SOX9 in invasive ductal carcinoma and metastatic breast cancer Experimental Biology and Medicine 2011 236 2 145 155 2-s2.0-79951658237 10.1258/ebm.2010.010086 21321311 · DOI
  59. [60]Wang Q.-Y. MiR-133b targets Sox9 to control pathogenesis and metastasis of breast cancer Cell Death & Disease 2018 9 7 752 2018 10.1038/s41419-018-0715-6 29970901 PMC6030174 · DOI
  60. [61]Lei B. Zhang Y. Liu T. Li Y. Pang D. Sox9 upregulation in breast cancer is correlated with poor prognosis and the CD44+/CD24-/low phenotype International Journal of Clinical and Experimental Pathology 2016 9 7
  61. [62]Lauth M. Toftgård R. Non-canonical activation of GLI transcription factors: Implications for targeted anti-cancer therapy Cell Cycle 2007 6 20 2458 2463 2-s2.0-35848938488 10.4161/cc.6.20.4808 17726373 · DOI
  62. [63]Ruiz i Altaba A. Mas C. Stecca B. The Gli code: an information nexus regulating cell fate, stemness and cancer Trends in Cell Biology 2007 17 9 438 447 2-s2.0-34848901657 10.1016/j.tcb.2007.06.007 17845852 PMC2601665 · DOI
  63. [64]Stecca B. Ruiz I Altaba A. Context-dependent regulation of the GLI code in cancer by HEDGEHOG and non-HEDGEHOG signals Journal of Molecular Cell Biology 2010 2 2 84 95 10.1093/jmcb/mjp052 2-s2.0-77952898697 20083481 PMC2905064 · DOI
  64. [65]Morris J. P. Wang S. C. Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma Nature Reviews Cancer 2010 10 10 683 695 10.1038/nrc2899 2-s2.0-77957150824 20814421 PMC4085546 · DOI
  65. [66]Hui C.-C. Angers S. Gli proteins in development and disease Annual Review of Cell and Developmental Biology 2011 27 513 537 2-s2.0-80054022786 10.1146/annurev-cellbio-092910-154048 21801010 · DOI
  66. [67]Strobel O. Hartwig W. Bergmann F. Anaplastic pancreatic cancer: presentation, surgical management, and outcome Surgery 2011 149 2 200 208 10.1016/j.surg.2010.04.026 2-s2.0-78751585082 20542529 · DOI
  67. [68]Clark C. J. Graham R. P. Arun J. S. Harmsen W. S. Reid-Lombardo K. M. Clinical outcomes for anaplastic pancreatic cancer: a population-based study Journal of the American College of Surgeons 2012 215 5 627 634 10.1016/j.jamcollsurg.2012.06.418 2-s2.0-84867825510 23084492 · DOI
  68. [69]Evans G. S. Chandler J. A. Cell proliferation studies in rat prostate I. the proliferative role of basal and secretory epithelial cells during normal growth The Prostate 1987 10 2 163 178 2-s2.0-0023253707 10.1002/pros.2990100208 3562347 · DOI
  69. [70]Ma F. Ye H. He H. H. SOX9 drives WNT pathway activation in prostate cancer The Journal of Clinical Investigation 2016 126 5 1745 1758 2-s2.0-84988535650 10.1172/JCI78815 27043282 PMC4855922 · DOI
  70. [71]Wang G. Lunardi A. Zhang J. Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion Nature Genetics 2013 45 7 739 746 2-s2.0-84879645484 10.1038/ng.2654 23727861 PMC4036521 · DOI · Paper page
  71. [72]Korinek V. Barker N. Morin P. J. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC−/− colon carcinoma Science 1997 275 5307 1784 1787 10.1126/science.275.5307.1784 2-s2.0-0030975671 9065401 · DOI
  72. [73]Matheu A. Collado M. Wise C. Oncogenicity of the developmental transcription factor Sox9 Cancer Research 2012 72 5 1301 1315 10.1158/0008-5472.CAN-11-3660 2-s2.0-84857700780 22246670 PMC3378515 · DOI
  73. [75]Forbes S. A. Beare D. Boutselakis H. COSMIC: Somatic cancer genetics at high-resolution Nucleic Acids Research 2017 45 1 D777 D783 2-s2.0-85016154270 10.1093/nar/gkw1121 27899578 PMC5210583 · DOI · Paper page
  74. [76]Balogh J. Victor D. Asham E. H. Hepatocellular carcinoma: a review Journal of Hepatocellular Carcinoma 2016 3 41 53 10.2147/JHC.S61146 27785449 PMC5063561 · DOI
  75. [77]Lin W. Chen Y.-L. Jiang L. Chen J.-K. Reduced expression of chemerin is associated with a poor prognosis and a lowed infiltration of both dendritic cells and natural killer cells in human hepatocellular carcinoma Clinical Laboratory 2011 57 11-12 879 885 2-s2.0-83455244583 22239017
  76. [78]Dettmer M. Itin P. Miny P. Gandhi M. Cathomas G. Willi N. Giant ectopic liver, hepatocellular carcinoma and pachydermia-a rare genetic syndrome? Diagnostic Pathology 2011 6 1, article no. 75 2-s2.0-81155157959 10.1186/1746-1596-6-75 21831298 PMC3162532 · DOI
  77. [79]Whittaker S. Marais R. Zhu A. X. The role of signaling pathways in the development and treatment of hepatocellular carcinoma Oncogene 2010 29 36 4989 5005 10.1038/onc.2010.236 2-s2.0-77956627711 20639898 · DOI
  78. [80]Kawaguchi Y. Sox9 and programming of liver and pancreatic progenitors The Journal of Clinical Investigation 2013 123 5 1881 1886 2-s2.0-84877106062 10.1172/JCI66022 23635786 PMC3635727 · DOI
  79. [81]Xue T.-C. Zhang L. Ren Z.-G. Sex-determination gene SRY potentially associates with poor prognosis but not sex bias in hepatocellular carcinoma Digestive Diseases and Sciences 2015 60 2 427 435 10.1007/s10620-014-3377-y 2-s2.0-84925028308 25274159 · DOI
  80. [82]Leung C. O.-N. Mak W.-N. Kai A. K. L. Sox9 confers stemness properties in hepatocellular carcinoma through Frizzled-7 mediated Wnt/β-catenin signaling Oncotarget 2016 7 20 29371 29386 2-s2.0-84969800124 27105493 PMC5045402
  81. [83]Coulouarn C. Cavard C. Rubbia-Brandt L. Combined hepatocellular-cholangiocarcinomas exhibit progenitor features and activation of Wnt and TGFβ signaling pathways Carcinogenesis 2012 33 9 1791 1796 10.1093/carcin/bgs208 2-s2.0-84865562740 22696594 · DOI
  82. [84]Cleere D. W. Triple-negative breast cancer: a clinical update Community Oncology 2010 7 5 203 211 10.1016/S1548-5315(11)70394-1 2-s2.0-77953546949 · DOI
  83. [85]Malhotra G. K. Zhao X. Edwards E. The role of Sox9 in mouse mammary gland development and maintenance of mammary stem and luminal progenitor cells BMC Developmental Biology 2014 14 1 p. 47 10.1186/s12861-014-0047-4 25527186 PMC4297388 · DOI
  84. [86]Ferlay J. Soerjomataram I. Dikshit R. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 International Journal of Cancer 2014 136 5 E359 386 10.1002/ijc.29210 25220842 · DOI · Paper page
  85. [87]Vallot C. Stransky N. Bernard-Pierrot I. A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression Journal of the National Cancer Institute 2011 103 1 47 60 2-s2.0-78651277534 10.1093/jnci/djq470 21173382 PMC3014990 · DOI
  86. [88]Aleman A. Adrien L. Lopez-Serra L. Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays British Journal of Cancer 2008 98 2 466 473 10.1038/sj.bjc.6604143 2-s2.0-38549123030 18087279 PMC2361432 · DOI
  87. [89]Sun J. Chen Z. Zhu T. Hypermethylated SFRP1, but none of other nine genes “informative” for western countries, is valuable for bladder cancer detection in Mainland China. Journal of Cancer Research and Clinical Oncology 2009 135 12 1717 1727 2-s2.0-70349767237 10.1007/s00432-009-0619-z 19565266 PMC11844782 · DOI
  88. [90]Yu J. Zhu T. Wang Z. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer Clinical Cancer Research 2007 13 24 7296 7304 2-s2.0-37549047612 10.1158/1078-0432.CCR-07-0861 18094410 · DOI
  89. [91]Son H. S. Shin Y. M. Park K. K. Correlation between HER2 overexpression and clinicopathological characteristics in gastric cancer patients who have undergone curative resection Gastric Cancer 2014 14 3 180 186 2-s2.0-84908098807 10.5230/jgc.2014.14.3.180 PMC4199885 25328763 · DOI
  90. [92]Yasui W. Oue N. Sentani K. Sakamoto N. Motoshita J. Transcriptome dissection of gastric cancer: Identification of novel diagnostic and therapeutic targets from pathology specimens Pathology International 2009 59 3 121 136 10.1111/j.1440-1827.2009.02329.x 19261089 · DOI
  91. [93]Sashikawa Kimura M. Mutoh H. Sugano K. SOX9 is expressed in normal stomach, intestinal metaplasia, and gastric carcinoma in humans Journal of Gastroenterology 2011 46 11 1292 1299 2-s2.0-84655163473 10.1007/s00535-011-0443-5 21861142 · DOI
  92. [94]Choi Y. J. Song J. H. Yoon J. H. Aberrant expression of SOX9 is associated with gastrokine 1 inactivation in gastric cancers Gastric Cancer 2014 17 2 247 254 2-s2.0-84898770149 10.1007/s10120-013-0277-3 23812904 · DOI
  93. [95]Ren X. Zheng D. Guo F. PPARγ suppressed Wnt/β-catenin signaling pathway and its downstream effector SOX9 expression in gastric cancer cells Medical Oncology 2015 32 4 p. 91 10.1007/s12032-015-0536-8 2-s2.0-84923789657 25720524 · DOI
  94. [96]Yoon J. H. Song J. H. Zhang C. Inactivation of the Gastrokine 1 gene in gastric adenomas and carcinomas The Journal of Pathology 2011 223 5 618 625 2-s2.0-79952553344 10.1002/path.2838 21341273 · DOI
  95. [97]Zhou C. Guo J. Zhu K. Elevated expression of SOX9 is related with the progression of gastric carcinoma Diagnostic Cytopathology 2011 39 2 105 109 10.1002/dc.21348 20301211 · DOI
  96. [98]Wang J. Xue X. Hong H. Upregulation of microRNA-524-5p enhances the cisplatin sensitivity of gastric cancer cells by modulating proliferation and metastasis via targeting SOX9 Oncotarget 2017 8 1 574 582 10.18632/oncotarget.13479 27880941 PMC5352179 · DOI
  97. [99]Liu J.-N. Shang Guan Y.-M. Qi Y.-Z. Wang H.-B. Zhang T.-G. Zhou C.-J. The evaluation of SOX9 expression and its relationship with carcinoembryonic antigen-related cell adhesion molecule 1 in gastric neoplastic and nonneoplastic lesions Annals of Diagnostic Pathology 2012 16 4 235 244 2-s2.0-84864131715 10.1016/j.anndiagpath.2011.10.003 22209504 · DOI
  98. [100]Serizawa T. Hirata Y. Hayakawa Y. Gastric metaplasia induced by Helicobacter pylori is associated with enhanced SOX9 expression via interleukin-1 signaling Infection and Immunity 2015 84 2 562 572 2-s2.0-84957712231 10.1128/IAI.01437-15 26644382 PMC4730566 · DOI
  99. [101]Amieva M. Peek R. M. Jr. Pathobiology of helicobacter pylori-induced gastric cancer Gastroenterology 2016 150 1 64 78 10.1053/j.gastro.2015.09.004 2-s2.0-84952683442 26385073 PMC4691563 · DOI
  100. [102]Wadhwa R. Song S. Lee J. Yao Y. Wei Q. Ajani J. A. Gastric cancer—molecular and clinical dimensions Nature Reviews Clinical Oncology 2013 10 11 643 655 10.1038/nrclinonc.2013.170 PMC3927982 24061039 · DOI
  101. [103]Sigal M. Rothenberg M. E. Logan C. Y. Helicobacter pylori activates and expands Lgr5+ stem cells through direct colonization of the gastric glands Gastroenterology 2015 148 7 1392 1404.e21 2-s2.0-84929211886 10.1053/j.gastro.2015.02.049 25725293 · DOI
  102. [104]Sun M. Uozaki H. Hino R. SOX9 expression and its methylation status in gastric cancer Virchows Archiv 2012 460 3 271 279 2-s2.0-84860322979 10.1007/s00428-012-1201-7 22331131 · DOI
  103. [105]Seymour P. A. Freude K. K. Tran M. N. SOX9 is required for maintenance of the pancreatic progenitor cell pool Proceedings of the National Acadamy of Sciences of the United States of America 2007 104 6 1865 1870 10.1073/pnas.0609217104 2-s2.0-33846910410 PMC1794281 17267606 · DOI
  104. [106]Furuyama K. Kawaguchi Y. Akiyama H. Continuous cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine pancreas and intestine Nature Genetics 2011 43 1 34 41 10.1038/ng.722 2-s2.0-78651228289 21113154 · DOI
  105. [107]Morris J. P. T. IV Cano D. A. Sekine S. Wang S. C. Hebrok M. Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice The Journal of Clinical Investigation 2010 120 2 508 520 10.1172/jci40045 2-s2.0-76649105065 20071774 PMC2810083 · DOI
  106. [108]Gnoni A. Licchetta A. Scarpa A. Carcinogenesis of pancreatic adenocarcinoma: precursor lesions International Journal of Molecular Sciences 2013 14 10 19731 19762 10.3390/ijms141019731 24084722 PMC3821583 · DOI
  107. [109]Hruban R. H. Adsay N. V. Albores-Saavedra J. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions The American Journal of Surgical Pathology 2001 25 5 579 586 10.1097/00000478-200105000-00003 2-s2.0-0035020633 11342768 · DOI · Paper page
  108. [110]Fero M. L. Rivkin M. Tasch M. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27Kip1-deficient Mice Cell 1996 85 5 733 744 2-s2.0-15844384256 10.1016/S0092-8674(00)81239-8 8646781 · DOI
  109. [111]Kiyokawa H. Kineman R. D. Manova-Todorova K. O. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of P27Kip1 Cell 1996 85 5 721 732 2-s2.0-15844415946 10.1016/S0092-8674(00)81238-6 8646780 · DOI
  110. [112]Nakayama K. Ishida N. Shirane M. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors Cell 1996 85 5 707 720 10.1016/s0092-8674(00)81237-4 2-s2.0-0030010591 8646779 · DOI
  111. [114]Bardeesy N. DePinho R. A. Pancreatic cancer biology and genetics Nature Reviews Cancer 2002 2 12 897 909 2-s2.0-0036883940 10.1038/nrc949 12459728 · DOI
  112. [115]Delous M. Yin C. Shin D. sox9b is a key regulator of pancreaticobiliary ductal system development PLoS Genetics 2012 8 6 e1002754 10.1371/journal.pgen.1002754 PMC3375260 22719264 · DOI
  113. [116]Vivanco I. Sawyers C. L. The phosphatidylinositol 3-kinase-AKT pathway in human cancer Nature Reviews Cancer 2002 2 7 489 501 10.1038/nrc839 2-s2.0-0036632368 12094235 · DOI
  114. [117]Balic A. Dorado J. Alonso-Gómez M. Heeschen C. Stem cells as the root of pancreatic ductal adenocarcinoma Experimental Cell Research 2012 318 6 691 704 2-s2.0-84857653680 10.1016/j.yexcr.2011.11.007 22119145 · DOI
  115. [118]Li C. Heidt D. G. Dalerba P. Identification of pancreatic cancer stem cells Cancer Research 2007 67 3 1030 1037 10.1158/0008-5472.can-06-2030 2-s2.0-33847052127 17283135 · DOI
  116. [119]Hermann P. C. Huber S. L. Herrler T. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer Cell Stem Cell 2007 1 3 313 323 10.1016/j.stem.2007.06.002 2-s2.0-34548455927 18371365 · DOI
  117. [120]Li C. Wu J. Hynes M. c-Met is a marker of pancreatic cancer stem cells and therapeutic target Gastroenterology 2011 141 6 2218.e5 2227.e5 10.1053/j.gastro.2011.08.009 2-s2.0-81855194258 21864475 · DOI
  118. [121]Rasheed Z. A. Yang J. Wang Q. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma Journal of the National Cancer Institute 2010 102 5 340 351 2-s2.0-77749292153 10.1093/jnci/djp535 20164446 PMC2831049 · DOI
  119. [122]Swindall A. F. Londoño-Joshi A. I. Schultz M. J. Fineberg N. Buchsbaum D. J. Bellis S. L. ST6Gal-I protein expression is upregulated in human epithelial tumors and correlates with stem cell markers in normal tissues and colon cancer cell lines Cancer Research 2013 73 7 2368 2378 2-s2.0-84876012263 10.1158/0008-5472.CAN-12-3424 23358684 PMC4038408 · DOI
  120. [123]Kondratyeva L. G. Chernov I. P. Zinovyeva M. V. Kopantzev E. P. Sverdlov E. D. Expression of master regulatory genes of embryonic development in pancreatic tumors Doklady Biochemistry and Biophysics 2017 475 1 250 252 2-s2.0-85028648914 10.1134/S1607672917040020 28864900 · DOI
  121. [124]Heldin C.-H. Vanlandewijck M. Moustakas A. Regulation of EMT by TGFβ in cancer FEBS Letters 2012 586 14 1959 1970 2-s2.0-84862770017 10.1016/j.febslet.2012.02.037 22710176 · DOI
  122. [125]Reichert M. Rustgi A. K. Pancreatic ductal cells in development, regeneration, and neoplasia The Journal of Clinical Investigation 2011 121 12 4572 4578 10.1172/jci57131 2-s2.0-84055193971 22133881 PMC3225990 · DOI
  123. [126]Arda H. E. Benitez C. M. Kim S. K. Gene regulatory networks governing pancreas development Developmental Cell 2013 25 1 5 13 2-s2.0-84876351067 10.1016/j.devcel.2013.03.016 23597482 PMC3645877 · DOI
  124. [127]Handorf A. M. Li W.-J. Fibroblast growth Factor-2 primes human mesenchymal stem cells for enhanced chondrogenesis PLoS ONE 2011 6 7 2-s2.0-79960789217 10.1371/journal.pone.0022887 e22887 PMC3144950 21818404 · DOI
  125. [128]Klöppel G. Basturk O. Schlitter A. M. Konukiewitz B. Esposito I. Intraductal neoplasms of the pancreas Seminars in Diagnostic Pathology 2014 31 6 452 466 10.1053/j.semdp.2014.08.005 25282472 · DOI
  126. [129]Kimura W. Sasahira N. Yoshikawa T. Muto T. Makuuchi M. Duct-ectatic type of mucin producing tumor of the pancreas - new concept of pancreatic neoplasia Hepato-Gastroenterology 1996 43 9 692 709 2-s2.0-0030001486 8799417
  127. [131]Cano D. A. Hebrok M. Zenker M. Pancreatic development and disease Gastroenterology 2007 132 2 745 762 10.1053/j.gastro.2006.12.054 2-s2.0-33847079324 17258745 · DOI
  128. [132]Heiser P. W. Lau J. Taketo M. M. Herrera P. L. Hebrok M. Stabilization of beta-catenin impacts pancreas growth Development 2006 133 10 2023 2032 10.1242/dev.02366 16611688 · DOI
  129. [133]Offield M. F. PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum Development 1996 122 3 983 995 8631275
  130. [134]Wang H. McKnight N. C. Zhang T. Lu M. L. Balk S. P. Yuan X. SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells Cancer Research 2007 67 2 528 536 2-s2.0-33846673020 10.1158/0008-5472.CAN-06-1672 17234760 · DOI
  131. [135]Huang Z. Hurley P. J. Simons B. W. Sox9 is required for prostate development and prostate cancer initiation Oncotarget 2012 3 6 651 663 10.18632/oncotarget.531 22761195 PMC3442290 · DOI
  132. [136]Thomsen M. K. Francis J. C. Swain A. The role of Sox9 in prostate development Differentiation 2008 76 6 728 735 2-s2.0-47749152282 10.1111/j.1432-0436.2008.00293.x 18557758 · DOI
  133. [137]Wang H. Leav I. Ibaragi S. SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion Cancer Research 2008 68 6 1625 1630 2-s2.0-40949145618 10.1158/0008-5472.CAN-07-5915 18339840 · DOI
  134. [138]Zhong W. Qin G. Dai Q. SOXs in human prostate cancer: implication as progression and prognosis factors BMC Cancer 2012 12 1 p. 248 10.1186/1471-2407-12-248 22703285 PMC3583167 · DOI
  135. [139]Qin G.-Q. He H.-C. Han Z.-D. Combined overexpression of HIVEP3 and SOX9 predicts unfavorable biochemical recurrence-free survival in patients with prostate cancer OncoTargets and Therapy 2014 7 137 146 2-s2.0-84893070359 24493929 PMC3908830
  136. [140]Thomsen M. K. Ambroisine L. Wynn S. SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation Cancer Research 2010 70 3 979 987 2-s2.0-76249098305 10.1158/0008-5472.CAN-09-2370 20103652 PMC3083842 · DOI
  137. [141]Xie Y. Lu W. Liu S. Crosstalk between nuclear MET and SOX9/β-catenin correlates with castration-resistant prostate cancer Molecular Endocrinology 2014 28 10 1629 1639 10.1210/me.2014-1078 25099011 PMC4179634 · DOI
  138. [142]Cai C. Wang H. He H. H. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer The Journal of Clinical Investigation 2013 123 3 1109 1122 2-s2.0-84874598190 10.1172/JCI66666 23426182 PMC3582143 · DOI
  139. [143]Luedeke M. Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status Human Molecular Genetics 2016 25 24 5490 5499 27798103 PMC5418832
  140. [144]Ricciardelli C. Oehler M. K. Diverse molecular pathways in ovarian cancer and their clinical significance Maturitas 2009 62 3 270 275 10.1016/j.maturitas.2009.01.001 2-s2.0-62849100542 19193504 · DOI
  141. [145]Kurman R. J. Ellenson L. H. Ronnettm B. M. Blaustein’s Pathology of the Female Genital Tract 2011 Springer 10.1007/978-1-4419-0489-8 · DOI
  142. [146]Irving-Rodgers H. F. Rodgers R. J. Extracellular matrix of the developing ovarian follicle Seminars in Reproductive Medicine 2006 24 4 195 203 2-s2.0-33748653563 10.1055/s-2006-948549 16944417 · DOI
  143. [147]Papanastasopoulos P. Repanti M. Damaskou V. Bravou V. Papadaki H. Investigating differentiation mechanisms of the constituent cells of sex cord-stromal tumours of the ovary Virchows Archiv 2008 453 5 465 471 2-s2.0-54249091506 10.1007/s00428-008-0677-7 18830622 · DOI
  144. [148]Parkin D. M. Whelan S. L. Ferlay J. Teppo L. Thomas D. B. Cancer incidence in five continents IARC Scientific Publications 2002 VIII 155 1 781 12812229
  145. [149]Boyle P. Langman J. S. ABC of colorectal cancer epidemiology British Medical Journal 2000 321 7264 805 808 2-s2.0-0034734896 10.1136/bmj.321.7264.805 11009523 PMC1118620 · DOI
  146. [150]Testa U. Pelosi E. Castelli G. Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells Medical Sciences 2018 6 2 p. 31 10.3390/medsci6020031 PMC6024750 29652830 · DOI
  147. [151]Steele G. Jr. Ravikumar T. S. Resection of hepatic metastases from colorectal cancer: biologic perspectives Annals of Surgery 1989 210 2 127 138 10.1097/00000658-198908000-00001 2-s2.0-0024390441 2667471 PMC1357818 · DOI
  148. [152]van der Flier L. G. Clevers H. Stem cells, self-renewal, and differentiation in the intestinal epithelium Annual Review of Physiology 2009 71 241 260 10.1146/annurev.physiol.010908.163145 2-s2.0-67651159312 18808327 · DOI
  149. [153]Adolph T. E. Tomczak M. F. Niederreiter L. Paneth cells as a site of origin for intestinal inflammation Nature 2013 503 7475 272 276 2-s2.0-84887621906 10.1038/nature12599 24089213 PMC3862182 · DOI · Paper page
  150. [154]Clevers H. C. Bevins C. L. Paneth cells: Maestros of the small intestinal crypts Annual Review of Physiology 2013 75 289 311 2-s2.0-84873672050 10.1146/annurev-physiol-030212-183744 23398152 · DOI
  151. [155]Blache P. Van De Wetering M. Duluc I. SOX9 is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses the CDX2 and MUC2 genes The Journal of Cell Biology 2004 166 1 37 47 2-s2.0-3142669010 10.1083/jcb.200311021 15240568 PMC2172132 · DOI
  152. [156]Bastide P. Darido C. Pannequin J. Sox9 regulates cell proliferation and is required for Paneth cell differentiation in the intestinal epithelium The Journal of Cell Biology 2007 178 4 635 648 10.1083/jcb.200704152 17698607 PMC2064470 · DOI
  153. [158]Shibata H. Toyama K. Shioya H. Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene Science 1997 278 5335 120 133 10.1126/science.278.5335.120 2-s2.0-0030843461 9311916 · DOI
  154. [159]Harada N. Tamai Y. Ishikawa T.-O. Intestinal polyposis in mice with a dominant stable mutation of the β-catenin gene EMBO Journal 1999 18 21 5931 5942 2-s2.0-0033230616 10.1093/emboj/18.21.5931 10545105 PMC1171659 · DOI
  155. [160]Candy P. A. Phillips M. R. Redfern A. D. Notch-induced transcription factors are predictive of survival and 5-fluorouracil response in colorectal cancer patients British Journal of Cancer 2013 109 4 1023 1030 2-s2.0-84883188923 10.1038/bjc.2013.431 23900217 PMC3749585 · DOI
  156. [161]Montorsi L. Guizzetti F. Alecci C. Loss of zfp36 expression in colorectal cancer correlates to wnt/β-catenin activity and enhances epithelial-to-mesenchymal transition through upregulation of zeb1, sox9 and macc1 Oncotarget 2016 7 37 59144 59157 2-s2.0-84991325615 27463018 PMC5312301

Cited by

Sorted by citations

Authors
Aguilar-Medina, M., Avendaño-Félix, M., Lizárraga-Verdugo, E., Bermúdez, M., Romero-Quintana, J. G., Ramos-Payan, R., Ruíz-García, E., & López-Camarillo, C.
Affiliations
  • Facultad de Ciencias Químico Biológicas, Universidad Autónoma de Sinaloa, Culiacán, Sinaloa, Mexico
  • Universidad Autónoma de Sinaloa (MX)
  • Laboratorio de Medicina Traslacional y Departamento de Tumores Gastro-Intestinales, Instituto Nacional de Cancerología. CDMX, Mexico
  • Posgrado en Ciencias Genómicas, Universidad Autónoma de la Ciudad de México, CDMX, Mexico
ORCID
Venue
Journal of Oncology
Publisher
Wiley
Published
2019-04-01
Volume
2019
Pages
1-16
ISSN
  • 1687-8450 (ISSN-L)
  • 1687-8469
DOI
10.1155/2019/6754040
PMC
PMC6463569
OpenAlex
W2935110656
Cited by
97
References
3
Citations by year
2026: 4 · 2025: 13 · 2024: 13 · 2023: 14 · 2022: 18 · 2021: 19 · 2020: 13 · 2019: 3
FWCI
1.26
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Consejo Nacional de Ciencia y Tecnología (290311, 575985, 304939, 220327)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
Keywords
SOX9, cancer stem cells, Sox transcription factors, SOX2, tumor progression, epigenetic reprogramming

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review